Sofinnova Partners
Sofinnova leads €4m seed round for Enthera
JDRF T1D Fund, managed by the Juvenile Diabetes Research Foundation, also takes part in the round
Sofinnova and 5AM lead £28m series-A for NodThera
UK drug discovery company will bring its leading drug candidate to the clinical trial stage
Andera leads $70m series-B for Crescendo Biologics
UK-based biotechnology company will progress its lead programme to the clinical stage
Sofinnova leads €26.5m round for EryDel
Existing shareholders Genextra and Innogest also take part in the investment round
Sofinnova hires in-house counsel from Eurazeo
Bordes will work in Sofinnova's support team alongside managing partner and COO Monique Salnier
Sofinnova leads €35.5m capital increase for Inventiva
Capital is drawn from Sofinnova Crossover Fund I, which held a final close on €275m in April 2018
Sofinnova holds €275m close for Crossover Fund 1
Vehicle will focus on biopharma and medical companies with EVs of €50-150m
French VC fundraising shifts towards sector specialisation
A number of specialist VC funds have held first or final closes in recent months, bringing distinct advantages and risks in equal measure
Sofinnova leads €6m series-A for SafeHeal
Fresh capital will be used to develop a clinical and regulatory market access programme for Colovac
Sofinnova holds final close for Sofinnova IB I
Having held a first close on €106m in February 2017, Sofinnova IB I closes on €125m
Sofinnova leads €12.3m round for Highlife
Following the deal, Sofinnova will become the largest shareholder in the business
Sofinnova promotes Richter to managing partner
Henrijette Richter joins the partnership after spending three years at the company
Sofinnova leads €11m fundraising for DNA Script
French investor now has 10 portfolio companies in the industrial biotechnology sector
Sofinnova promotes Seghezzi to managing partner
Graziano Seghezzi joins existing managing partners Antoine Papiernik, Denis Lucquin and Monique Saulnier
Antoine Papiernik appointed chair of Sofinnova Partners
Denis Lucquin will continue to be part of Sofinnova, staying on as managing partner
Sofinnova's Avantium launches IPO with €277m market cap
IPO brought the renewable energy specialist a capital increase of €103m
Gimv, Sofinnova in €43.5m round for Breath Therapeutics
Company will use the financing to conduct phase III trials of its inhalation therapy in Europe and the US
France-based Sofinnova holds €106m close for biotech fund
Sofinnova Industrial Biotech I is dedicated to VC investments in renewable chemistry
BPI, Sofinnova, Novo Nordisk-backed Lysogene launches IPO
Sofinnova entered the group in 2014, leading a €16.5m round for the group
MyTomorrows raises €10m from EQT, Octopus et al.
Latest funding round brings the total raised by the startup to $22.14m
MPM in iOmx Therapeutics' €40m series-A
Proceeds will be used to develop proprietary product candidates
Ysios et al. raise €15.5m series-B for CorWave
Backers include existing shareholders Sofinnova Partners, BPI France and Seventure Partners
EdRip leads €34m series-B for MedDay
French biotech is to begin the third US testing phase for its multiple sclerosis drug
Sofinnova leads €22m series-A for Enyo Pharma
Round featured €5m contribution from BPI France’s €173m healthcare-focused InnoBio fund